Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for chronic inflammatory cardiomyopathy
2022-003912-99Phase 3Active
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in inflammatory cardiomyopathy, myocarditis and Cardiomyopathies comparing Colchicine + optimal medical therapy with Placebo + optimal medical therapy (2 arms). Primary endpoint: Positive response to treatment at 6 months. Started Feb 2023; status: active.
02
Drugs
colchicine
03
Conditions
inflammatory cardiomyopathymyocarditisCardiomyopathies
Beyond the preview
Go deeper on 2022-003912-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003912-99.